Related references
Note: Only part of the references are listed.Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Sonia S. Anand et al.
LANCET (2018)
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Ammar Majeed et al.
BLOOD (2017)
Heparin neutralizer Anticoagulant reversal agent
V. Muralidharan-Chari et al.
DRUGS OF THE FUTURE (2016)
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ciraparantag for enoxaparin reversal: Adding to the evidence
Jeffrey I. Weitz et al.
THROMBOSIS RESEARCH (2016)
Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin
Jack E. Ansell et al.
THROMBOSIS RESEARCH (2016)
National Trends in Ambulatory Oral Anticoagulant Use
Geoffrey D. Barnes et al.
AMERICAN JOURNAL OF MEDICINE (2015)
Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects
Yan Song et al.
CLINICAL THERAPEUTICS (2015)
PER977 REVERSES LOW MOLECULAR WEIGHT HEPARIN IN ADDITION TO IIA AND XA NEW ORAL ANTICOAGULANTS
James C. Costin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
Stephan Glund et al.
LANCET (2015)
Idarucizumab for Dabigatran Reversal
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Deborah M. Siegal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab
Markus Honickel et al.
THROMBOSIS AND HAEMOSTASIS (2015)
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran
Stephan Glund et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
David J. Graham et al.
CIRCULATION (2015)
Activated prothrombin complex concentrate for dabigatran-associated bleeding
Sam Schulman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants
Adam Cuker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
M. Levi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
E. M. H. Schmitz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
Jack E. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays
Isabelle Gouin-Thibault et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban A cross-sectional pharmacodynamic study based on peak and trough plasma levels
Suzanne J. Francart et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro
Elisabeth Perzborn et al.
THROMBOSIS RESEARCH (2014)
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
Hein Heidbuchel et al.
EUROPACE (2013)
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
Stuart J. Connolly et al.
EUROPEAN HEART JOURNAL (2013)
Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness
K. Yada et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
T. Baglin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients REPLY
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery Findings from the ORTHO-TEP registry
Jan Beyer-Westendorf et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Joachim Stangier et al.
BLOOD COAGULATION & FIBRINOLYSIS (2012)
Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology
Trevor Baglin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Executive Summary Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Gordon H. Guyatt et al.
CHEST (2012)
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study
Masatsugu Hori et al.
CIRCULATION JOURNAL (2012)
National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
Kate Kirley et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2012)
Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
I. Pragst et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
Graeme J. Hankey et al.
LANCET NEUROLOGY (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
Raphael Marlu et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
Menno V. Huisman et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
Keith A. A. Fox et al.
EUROPEAN HEART JOURNAL (2011)
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
Edith Nutescu et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran
Wei Zhou et al.
STROKE (2011)
Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients
Farjah H. AlGahtani et al.
ANNALS OF SAUDI MEDICINE (2010)
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Michael Rud Lassen et al.
LANCET (2010)
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Does timing of surgery matter in fragility hip fractures?
F. Leung et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
Jeffrey I. Weitz et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
Yu Chen Barrett et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
Jeffrey S. Ginsberg et al.
JOURNAL OF ARTHROPLASTY (2009)
Length of stay, mortality, morbidity and delay to surgery in hip fractures
K. A. Lefaivre et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)
Alexander G. G. Turpie et al.
THROMBOSIS AND HAEMOSTASIS (2009)
The story of the discovery of heparin and warfarin
Douglas Wardrop et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar et al.
LANCET (2008)
Bivalirudin during primary PCI in acute myocardial infarction
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Bengt I. Eriksson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
Michael R. Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial
Bengt I. Eriksson et al.
LANCET (2007)
Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography
Guy Young et al.
BLOOD COAGULATION & FIBRINOLYSIS (2007)
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
Jonathan Mant et al.
LANCET (2007)
Does delay in surgery after hip fracture lead to worse outcomes? A multicenter survey
Victor Novack et al.
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE (2007)
Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation
Elaine M. Hylek et al.
CIRCULATION (2007)
Bivalirudin for patients with acute coronary syndromes
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Measurement of patients' bivalirudin plasma levels by a Thrombelastograph® ecarin clotting time assay:: A comparison to a standard activated clotting time
RC Carroll et al.
ANESTHESIA AND ANALGESIA (2006)
Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia
CH Dang et al.
PHARMACOTHERAPY (2006)
Clinical use of plasma and plasma fractions
RK Spence
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2006)
Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation
AL Waldo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
AT Cohen et al.
THROMBOSIS AND HAEMOSTASIS (2005)
Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall
BF Gage et al.
AMERICAN JOURNAL OF MEDICINE (2005)
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients
M Pirmohamed et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant
DF O'Shaughnessy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Share Paper
